In-Hospital Outcomes After Transcatheter Aortic Valve Implantation in Patients With Versus Without Chronic Thrombocytopenia

Abstract

Patients with chronic thrombocytopenia (cTCP) were excluded from the pivotal transcatheter aortic valve implantation (TAVI) trials. The National Inpatient Sample was queried and propensity score matching was performed to evaluate the prevalence and impact of cTCP on in-hospital clinical outcomes after TAVI. The main outcome was in-hospital mortality in patients with versus without cTCP. Among 38,855 TAVI hospitalizations, 7,105 had a diagnosis of cTCP (18.3%). In-hospital mortality was similar in both groups (OR_adjusted 0.79; 95% confidence interval [CI] 0.57 to 1.09); however, cTCP was associated with higher risk of acute kidney injury (OR_adjusted 1.29; 95% CI 1.08 to 1.54), vascular complications (OR_adjusted 1.99; 95% CI 1.22 to 3.25), perioperative blood product transfusion (OR_adjusted 1.69; 95% CI 1.42 to 2.01), cardiac tamponade (OR_adjusted 4.04; 95% CI 1.51 to 10.82), cardiogenic shock (OR_adjusted 1.52; 95% CI 1.07 to 2.15), and use of extracorporeal membrane oxygenation (OR_adjusted 2.32; 95% CI 1.1 to 4.9). In conclusion, cTCP is common in patients who underwent TAVI and is associated with worse postprocedure clinical outcomes, however, with similar in-hospital mortality.